Previous Close | 8.53 |
Open | 8.48 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 8.39 - 8.68 |
52 Week Range | 8.37 - 36.25 |
Volume | |
Avg. Volume | 807,925 |
Market Cap | 445.899M |
Beta (5Y Monthly) | 2.76 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
4D Molecular Therapeutics (FDMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.